Fresh analysis indicates that patients who come off new weight-loss injections like Wegovy and Mounjaro can put back on lost weight at a significantly accelerated pace than those who stop conventional diet and exercise regimens.
Published data in a leading health publication demonstrates that while obese individuals often shed substantial amounts of their total mass while undergoing treatment, the mass is regained at an average rate of 0.8 kg per month once they quit.
"People purchasing such medications should be informed of the potential of fast weight regain when the therapy is stopped," warns lead investigator Dr. Susan Jebb.
That rate of recovery suggests a reversion to pre-treatment weight within about 18 months.
Analyzing Treatments
The research, which looked at 37 of trials involving over 9,000 of participants, compared the outcomes of these new drugs with other pills.
Scientists point out that people who lose weight through dieting typically experience a less rapid creep back—approximately 0.1 kg a month—after stopping.
The Reason for the Rapid Rebound
Experts propose the way of the drugs is key to understanding the amplified rebound.
The injections imitate a natural hormone called GLP-1, which controls feelings of fullness.
"Long-term administration of GLP-1 levels far above than normal could lead to the system to produce less of its own natural GLP-1, and could diminish responsiveness to its actions," noted Dr. Adam Collins, a dietetics researcher.
"Stopping of this medication results in hunger is uncontrolled, making excessive eating much more probable."
A Lifelong Issue?
The NHS suggest the injections for people with obesity-related health risks, accompanied by prescribed diet and exercise modifications.
Many experts argue that, given the likelihood of relapse, the therapy might need to be ongoing.
This perspective is reinforced by pharmaceutical companies, who say that the results "underscore the long-term nature of excess weight," comparing it to managing conditions like hypertension.
User Accounts
Individuals who have stopped the jabs describe a sudden resurgence of cravings.
"It was like something flipping and I was suddenly starving," said one woman.
This challenge is exacerbated if patients have not developed lasting dietary or behavioural modifications during treatment.
Widespread Interest
Recent estimates indicate that a significant number of people in the UK have used weight-loss jabs in the past year, with demand continuing to grow.
- Use is higher among women compared to men.
- The 40s and 50s demographic shows the highest level of interest.
- A large proportion access the drugs through private healthcare rather than the NHS.
Finally, experts stress that while GLP-1 drugs are powerful agents for weight loss, they are not a magic solution and long-term success likely depends on integrated lifestyle management.
